OpportunityAnalyzer:Uveitis Opportunity Analysis and Forecasts to 2026

Summary

Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatment of uveitis. Based on the diverse nature of uveitis , there is a high unmet need for varied therapy approaches. Significant efforts are being made to develop new treatments for uveitis, as current pharmacologic management, which is dominated by competitively priced corticosteroids and also immunosuppressive drugs, is notorious for the development of adverse side effects.

GlobalData estimates the drug sales for uveitis in 2016 were approximately $416.5M across the 7MM covered in this report. Over the 10year forecast period, the market is expected to grow to $897.1M at a CAGR of 8.0%.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/opportunityanalyzeruveitisopportunity-forecasts2026-market-110

The anticipated introduction of five new drugs will further drive the market by offering novel treatment mechanisms, including new drug delivery routes and novel, noncorticosteroid drug molecules. These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth.

Scope

Overview of uveitis: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized uveitis market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments including noninfectious mild and moderate anterior uveitis, noninfectious severe anterior uveitis, noninfectious intermediate, posterior and panuveitis, forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the uveitis therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for uveitis therapy. The most promising candidate in Phase III and Phase II/III development is profiled.
Analysis of the current and future market competition in the global uveitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to

• Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global uveitis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global uveitis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/opportunityanalyzeruveitisopportunity-forecasts2026-market-110

Table of content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 8
2 Executive Summary 9
2.1 Significant Growth Is Expected in the Uveitis Market from 2016 to 2026 9
2.2 R&D and Corporate Strategies Within the Uveitis Market 11
2.3 A LongActing Treatment That Permanently Controls Inflammation, With a Good Short and LongTerm Safety Profile, Remains Elusive 12
2.4 Market Opportunities for New Entrants 13
2.5 LateStage Pipeline Drugs Entering the Uveitis Market Will Be a Key Driver of Growth 14
2.6 What Do Physicians Think? 16
3 Introduction 19
3.1 Catalyst 19
3.2 Related Reports 19
4 Disease Overview 20
4.1 Etiology and Pathophysiology 20
4.1.1 Etiology 21
4.1.2 Pathophysiology 24
4.2 Classification or Staging Systems 26
4.2.1 Uveitis and Systemic Diseases 27
4.3 Symptoms 29
4.4 Prognosis 30
4.5 Quality of Life 31
5 Epidemiology 32
5.1 Disease Background 32
5.2 Risk Factors and Comorbidities 33
5.3 Global and Historical Trends 34
5.3.1 US 36
5.3.2 5EU 37
5.3.3 Japan 38
5.4 Forecast Methodology 39
5.4.1 Sources 40
5.4.2 Forecast Assumptions and Methods 44
5.5 Epidemiological Forecast for Uveitis 20162026 54
5.5.1 Diagnosed Incident Cases of Uveitis 54
5.5.2 Diagnosed Prevalent Cases of Uveitis 55
5.5.3 AgeSpecific Diagnosed Prevalent Cases of Uveitis 56
5.5.4 SexSpecific Diagnosed Prevalent Cases of Uveitis 57
5.5.5 Diagnosed Prevalent Cases by Anatomical Site of Inflammation 58
5.5.6 Diagnosed Prevalent Cases by Etiology 59
5.6 Discussion 60
5.6.1 Epidemiologi

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/opportunityanalyzeruveitisopportunity-forecasts2026-market-110

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports